We investigated ten --eleven translocation 2 (TET2) mutations in acute myeloid leukemia (AML), their correlation with other gene mutations and prognostic value. By deep-sequencing, 131 somatic TET2 mutations were identified in 87/318 (27.4%) patients. Of 87 mutated cases, 44 (50.6%) carried two mutations. TET2 mutations were concomitantly observed with mutations in NPM1, FLT3-ITD, FLT3-TKD, JAK2, RUNX1, CEBPA, CBL and KRAS. However, TET2 mutations rarely concomitantly occurred with IDH1mut or IDH2mut (2/251 or 0/184; P ¼ 0.046 and P ¼ 0.003, respectively). TET2 mutations were associated with normal karyotype AML (CN-AML) (62/206 (30.1%) CN-AML vs 20/107 (18.7%) aberrant karyotype; P ¼ 0.031), higher white blood cell count (mean 65.3 vs 40.3 Â 10 9 /l, P ¼ 0.023), lower platelet count (mean 68.6 vs 92.4 Â 10 9 /l, P ¼ 0.03) and higher age (67.5 vs 65.2 years, Po0.001). Survival analyses were restricted to de novo CN-AML patients (n ¼ 165) and showed inferior event-free survival (EFS) of TET2 mutations compared with TET2wt (median: 6.7 vs 18.7 months, P ¼ 0.009). This negative effect of TET2 mutation on EFS was particularly observed in patients p65 years (median: 8.9 months vs not reached (n.r.), P ¼ 0.027) as well as in patients of the European LeukemiaNet favorable-risk subgroup, that is, patients harboring mutated CEBPA and/or mutated NPM1 without FLT3-ITD (median: 10.3 vs 41.3 months, P ¼ 0.048). These data support a role for TET2 as an important prognostic biomarker in AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic progenitor cells, characterized by an early block of myelopoiesis and excessive proliferation of blasts frequently resulting in hematopoietic insufficiency (granulocytopenia, thrombocytopenia or anemia) with or without leukocytosis. 1 --5 In addition to specific chromosomal translocations, such as t(8;21)(q22;q22) or t(15;17)(q22;q21), and inversions, for example, inv(16)(p13q22) or inv(3)(q21q26), a broad range of molecular alterations with prognostic impact has been described in various genes, such as FLT3, CEBPA and NPM1. 6 --10 Mutations in the ten --eleven translocation 2 (TET2) gene, first described in 2008, 11, 12 have been identified in a variety of myeloid malignancies and are amongst the most frequently acquired molecular aberrations associated with myelodysplastic syndrome (MDS). 13, 14 Most of the described TET2 mutations probably cause inactivation of the TET2 protein, therefore a tumor-suppressor function for this gene was suggested. 15, 16 It has been recently reported that all members of the TET gene family, including TET2, catalyze the conversion of 5-methylcytosine to 5-hydroxymethylcytosine. 17 Thus, TET2 mutations possibly alter hematopoietic stem cell functions and development by epigenetic modifications. 18 However, prognostic impact of TET2 mutations remains controversial, because some studies have suggested a favorable prognostic relevance, whereas others were reporting no significant effect concerning survival in MDS. 12, 13, 19 Nibourel et al. 20 found no significant correlation of the TET2 mutation status with survival outcomes in patients with previously untreated de novo AML who achieved complete remission. According to the newly defined European LeukemiaNet (ELN) classification of AML, 21 Metzeler et al. 22 reported TET2 mutations being associated with inferior outcomes in the ELN favorable-risk group, but not in the intermediate-I-risk group.
To date, only limited data are available on the role of TET2 mutations in AML, in particular within the context of other AML-associated gene mutations. Moreover, prognostic data are preliminary and molecular investigation is challenging and laborintensive with standard sequencing techniques. Here, we applied a massively parallel amplicon next-generation deep-sequencing technology and investigated a cohort of 318 patients with AML (de novo AML, s-AML and t-AML) for mutations in TET2. We could demonstrate TET2 as an important prognostic biomarker in de novo AML patients with normal karyotype (CN-AML), because TET2 mutations were associated with inferior event-free survival (EFS), particularly in patients within the newly defined ELN favorableprognostic-risk group category.
PATIENTS AND METHODS

Patients and study design
The study comprised of 318 AML patient samples, including 255 de novo AML, 38 s-AML and 25 t-AML cases, sent to the MLL Munich Leukemia Laboratory for diagnostic assessment between August 2005 and November 2010. According to cytogenetically defined MRC criteria, 23 11 patients of this cohort were assigned to the favorable-prognostic-risk group, 250 patients to the intermediate-prognostic-risk group and 52 to the poorprognostic-risk group. In detail, 206 patients had a normal karyotype, 34 patients had a complex aberrant karyotype, 5 patients had a t(15;17), 6 patients had a t(8;21) and 62 patients carried other chromosomal aberrations. For 5/318 patients, the karyotype was not available. The cohort included 160 female and 158 male patients. The median age was 66.4 years (ranging from 19.7 to 89.8 years). Incidence of TET2 mutations and correlation with molecular mutations in NPM1, FLT3-TKD, IDH1, IDH2, JAK2, RUNX1, CEBPA, CBL and KRAS, as well as with FLT3-ITD, were investigated for this cohort. For survival analyses focusing on TET2 only, the cohort of de novo CN-AML patients was further investigated. This subgroup accordingly comprised of 170 cases (for 165 patients clinical follow-up data were available), 93 female and 77 male patients, with a median age of 65.0 years (ranging from 21.7 to 85.8 years). The recently defined ELN criteria further divide CN-AML patients into the favorable-risk group, that is, patients that have mutated CEBPA and/or NPM1 without FLT3-ITD and the intermediate-I-risk group, that is, patients with wild-type CEBPA and wildtype NPM1 and/or FLT3-ITD. 21 According to these criteria, 81 patients of our cohort were classified to the favorable-risk category and 84 cases to the intermediate-I-risk category.
For the following molecular analyses, bone marrow or peripheral blood mononuclear cells were enriched using a Ficoll density gradient. The study design adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board before its initiation.
Amplicon preparation for TET2 investigations TET2 amplicons suitable for 454 next-generation sequencing were prepared as described previously. 24 Briefly, all coding exons of TET2 (Transcript-ID ENST00000380013) were represented by 27 distinct amplicons, which were amplified in preconfigured 96-well primer plates (Roche Applied Science, Penzberg, Germany) using the FastStart High Fidelity PCR System kit (Roche Applied Science). Multiple molecular barcodes (MIDs) were used to distinguish between patients. After amplification, each PCR product was individually purified using Agencourt AMPure XP beads (Beckman Coulter, Krefeld, Germany) and patient-specific amplicon pools were generated by combining each of the 27 amplicons for each patient sample. Further, individual lane pools were generated by combining equimolar amounts of up to four patient samples for each lane. The concentration of individual lane pools was assessed using the Quant-iT PicoGreen dsDNA kit (Invitrogen, Carlsbad, CA, USA) and was adjusted to 1 Â 10 9 molecules/ml. Primers and cycler protocol used were previously described. 24 Next-generation sequencing 454 next-generation sequencing was performed as described previously. 24 Briefly, final lane pools were prepared for the emulsion PCR by diluting the amplicon pools to a concentration of 4 Â 10 6 molecules/ml. The libraries were subsequently processed using the GS FLX Titanium Series Lib-A SV method (Roche Applied Science). Forward (A beads) and reverse (B beads) reactions were carried out using 2 000 000 beads per emulsion oil tube. The amplification reaction, breaking of the emulsions and enrichment of beads carrying amplified DNA were performed using the workflow as recommended by the manufacturer. However, A beads and B beads were processed separately during breaking and enrichment processes. Finally, up to four patient samples were loaded per lane on an 8-lane PicoTiterPlate on the GS FLX sequencer instrument.
Data analyses and detection of variants
All data were generated using the GS FLX sequencer instrument software versions 2.3. and 2.5. Image processing and amplicon pipeline analyses were performed using default settings of the GS RunBrowser software versions 2.3 and 2.5 (Roche Applied Science). Sequence alignment and variant detection were performed using the GS Amplicon Variant Analyzer software versions 2.3 and 2.5 (Roche Applied Science). The results were further processed and visualized in R/Bioconductor using the package R453Plus1Toolbox (version 12.2.0) 25 and the Sequence Pilot software versions 3.4.0 and 3.4.2 (JSI medical systems, Kippenheim, Germany). For the detection of variants, filters were set to display sequence variances occurring in more than 1% of bidirectional sequencing reads per amplicon. Variants and single nucleotide polymorphisms (SNPs) within introns were not scored. TET2-missense variations were only considered as mutations when located within the two evolutionary conserved regions as described by Langemeijer et al. 13 In cases with available remission samples, missense mutations were analyzed for their presence in the germline DNA. 24 Chromosome banding analysis and fluorescence in situ hybridization (FISH) analyses Chromosome banding analysis was performed following standard methods. 32 Complex karyotypes were defined by presence of at least three clonal cytogenetic abnormalities. FISH analyses on interphase nuclei were performed using BACs covering the TET2 gene (RP11-351K6 and RP11-16G16; BlueGnome, Cambridge, UK) and a commercially available TET2 probe (MetaSystems, Altlussheim, Germany). Both assays were validated on samples with TET2 deletions proven by SNP 6.0 DNA microarray analysis (Affymetrix, Santa Clara, CA, USA; data not shown).
Molecular mutation analysis
Prediction of functional effect of TET2 missense mutations
In order to predict the deleterious effects of amino acid substitutions in TET2, the PolyPhen-2 application was used. 33 PolyPhen-2 applies various sequence-and structure-based features to predict the phenotypic consequences of missense mutations. PolyPhen-2 uses empirically derived rules to predict the functional effects of non-synonymous SNPs: (i) probably damaging, that is, it is with high confidence supposed to affect protein function or structure, (ii) possibly damaging, that is, it is supposed to affect protein function or structure, (iii) benign, that is, most likely lacking any phenotypic effect, (iv) unknown, that is, when in some rare cases, the lack of data does not allow PolyPhen-2 to make a prediction.
Methylation-specific polymerase chain reaction
Methylation status of two CpG islands in the TET2 promotor region was investigated in 48 patients. Methylation-specific PCR was performed as described previously. 34 For bisulfite conversion the EpiTect kit (Qiagen, Hilden, Germany) was used. Primers were designed according to AbdelWahab et al. 35 Methylated and unmethylated forward primers were fluorescently labeled, respectively. Subsequent PCR was performed using the FastStart High Fidelity PCR System kit (Roche Applied Science). Methylation status was assessed by fragment analysis of the resulting PCR products using the 3130xl Genetic Analyzer (Applied Biosystems, Life Technologies, Carlsbad, CA, USA). Results were analyzed with the GeneMapper ID v3.2 Software (Applied Biosystems, Life Technologies).
Statistical analysis
Overall survival (OS) and EFS were calculated according to Kaplan --Meier estimates. Comparison of survival was based on the two-sided log rank test. OS was the time from diagnosis to death or last follow-up and EFS was the time from diagnosis to treatment failure, relapse or death, or last follow-up, respectively. Relapse of AML was defined according to the International Working Group criteria published by Cheson et al. 36 Cox regression analysis was performed for OS and EFS with different parameters as covariables. Parameters that were significant in univariable analyses (Po0.05) were included in multivariable analysis. Dichotomous variables were compared between different groups by the w 2 -test and continuous variables by the student's t-test. Spearman's rank correlation was used to analyze correlations between continuous parameters. Results were significant at a level of Po0.05 at both sides. SPSS software version 14.0.1 was used for statistical analysis (SPSS, Chicago, IL, USA).
RESULTS
Distribution and characteristics of TET2 mutations in AML
The frequency and nature of TET2 mutations were investigated in a cohort of 318 AML patients. Missense variations were only TET2 mutations in AML: incidence and prognosis S Weissmann et al included in analyses when located within one of the two evolutionary conserved regions. According to Langemeijer et al., 13 the first conserved domain (CD1, Figure 1 ) is spanning amino acids 1104 --1478 and the second domain (CD2, Figure 1 ) amino acids 1845 --2002.
After excluding 14 known polymorphisms, 6 silent mutations and 7 missense mutations located outside the conserved regions (Supplementary Table 1 ), we observed 131 mutations of TET2 in 87/318 (27.4%) patients. Of these 131 mutations, 14 occurred in more than one patient (Supplementary Table 1 ). In total, 112 distinct mutations were detected (Supplementary Table 1 ). The 131 variants were composed of 80 point mutations (61.1%), 29 deletions (22.1%, ranging from 1 to 35 bp), 21 duplications (16.0%, ranging from 1 to 58 bp) and 1 insertion (0.8%, 1 bp). In consequence, these variations led to 49 nonsense mutations (37.4%), 45 frameshift mutations (34.4%), 35 putative missense mutations (26.7%) and 2 splice site mutations (1.5%). These mutations were spread across all exons. The majority of mutations (74/131, 56.5%) were located in the largest exons 3 and 11 ( Figure 1 ). However, according to their size, the highest density of mutations was within exons 5 --9 (34/131, 26%).
Next, we investigated the mutational load. For all amplicons, a median sequencing coverage of 731-fold (range: 587 --851-fold) was achieved. The mutational burden was in median 46% (range 5 --98%). Only in eight cases was a mutational load o20% (median: 7.3%, range 5 --10%) observed, which is below the detection level of Sanger sequencing. Only 11/131 (8.4%) mutations revealed a mutational load of 460% indicating homozygous alterations (Supplementary Table 1) .
Of the total 87 cases with TET2 mutations, 44 (50.6%) patients carried two different variants. No patient with more than two TET2 mutations was detected. In four patients, two different TET2 mutations each were covered by the same amplicon. In these cases, the two mutations could be assigned to different alleles as according to their location on distinct sequencing reads.
Putative missense mutations and analysis of remission controls In patients with 50% load of a missense variant with location inside or outside the two conserved domains, we aimed at analyzing their germline or somatic origin. From 10 out of 33 (30.3%) of such cases, either bone marrow or peripheral blood samples were available (Table 1 ). Sequencing analyses revealed that 2/10 (20%) of the investigated variations (Glu432Gly and Pro1962Leu) were present in a remission sample and therefore were regarded as germline. For five additional putative missense mutations located outside the two conserved domains, no remission material was available. But according to Metzeler et al., 22 it seems likely that these five variations were also of germline origin.
For the case with the Ile1873Thr mutation, no remission material was available. However, in an MDS patient not included in the current study, the mutational burden of the same mutation increased from 19 to 40% within 1 month. Therefore, and because of its location within the second conserved region, the Ile1873Thr variation was regarded as being more probably an acquired alteration rather than a rare polymorphism.
Prediction of functional effect of TET2 missense mutations All the 37 distinct TET2 missense variations detected in our cohort were analyzed with the PolyPhen-2 tool to predict possible impact of the resulting amino acid substitution on the structure and/or function of the TET2 protein. Of the 7 mutations located outside the two conserved domains, 2 (28.5%) were predicted to be benign, 3 (42.9%) to be possibly damaging and 2 (28.5%) to be probably damaging. The Pro1962Leu variation, which was observed to be of germline origin, was predicted to be benign. Of the 29 distinct missense mutations within the conserved domains, only 1 (Arg1161Ser) was predicted to be benign. Of the remaining 28 mutations, 7 (25%) were predicted to be possibly damaging and 21 (75%) were probably damaging (Supplementary Table 2 ). Taken together, these results revealed that the vast majority (96.6%) of the observed missense mutations within the conserved regions probably have a damaging effect on the TET2 protein structure and/or function. However, missense variations located outside the conserved domains were predicted to be not necessarily benign.
FISH analyses and TET2 deletions in AML In all, 301 (94.7%) out of the total 318 patients were investigated using FISH for TET2 deletions. Deletions of TET2 were identified in 19/301 (6.3%) patients (data not shown). Of these patients, 7/19 (36.8%) carried additional mutations in TET2. In detail, one of the seven patients harbored two mutations in TET2, both of which had a mutational burden of o10% (6% and 7%, respectively). In all, three out of these seven cases additionally harbored one heterozygous TET2 mutation. The remaining three patients showed one homozygous mutation in TET2. However, 12 patients that exhibited a TET2 deletion showed no sequence variation in TET2 (data not shown). In one patient carrying a homozygous TET2 mutation, an uniparental disomy of 4q was found by a complementary SNP 6.0 microarray analysis (Supplementary Figure 1) .
Associations with other molecular mutations Data on other mutations were available in subcohorts as follows:
For 51 patients (16.0%), all of the listed genes were investigated. TET2 mutations were concomitantly observed together with Supplementary Figure 2) . However, TET2 mutations occurred highly infrequently together with mutations in IDH1 (2/251 cases analyzed in parallel, P ¼ 0.046) and were mutually exclusive of IDH2 mutations (0/184, P ¼ 0.003). Further, JAK2 mutations (n ¼ 4) were observed only in cases with TET2 mutations (4/43 vs 0/97, P ¼ 0.008). Three out of four patients with JAK2/TET2 double mutations were patients with s-AML after myeloproliferative neoplasm, and so presence of JAK2 mutations was not surprising. Interestingly, our data showed that all three s-AML patients gained a TET2 mutation during blast crisis, which underlines the hypothesis of TET2 mutations acting as supporting mutations. When only de novo CN-AML patients were investigated, no association between TET2 and JAK2 mutations could be observed (P ¼ 0.306, Supplementary Table 3) .
Clinical associations
The association between TET2 mutational status and clinical variables is shown in Methylation of the TET2 promotor Methylation-specific PCR assays were performed to investigate whether in patients carrying only one heterozygous TET2 mutation the wild-type allele was silenced by methylation. Therefore, 24 patients of the cohort harboring only one heterozygous TET2 mutation that showed no TET2 deletion in FISH analyses were analyzed for their methylation status in TET2 compared with 24 TET2 wild-type patients. In this cohort, we did not identify methylation at either of the two CpG islands within the TET2 promotor region, neither in patients harboring a TET2 mutation nor in TET2 wild-type patients (data not shown). This data suggested that TET2 promotor methylation is not commonly involved as a mechanism of inactivating the remaining wild-type allele in patients harboring one heterozygous TET2 mutation.
Survival analyses
As TET2 mutations had been most frequently detected in de novo CN-AML patients, 37, 38 we focused on these patients for survival analysis (n ¼ 170; for 165 patients clinical follow-up data were available). Clinical associations within this group were comparable to those within the total cohort, except for white blood cell count, which was only nonsignificantly different between patients with and without TET2 mutations (mean ± s.d. 68.9 ± 80.9 vs 47.6 ± 51.2 Â 10 9 /l, P ¼ 0.064, Supplementary Table 3) . Figure 2a) . However, TET2-mutated patients exhibited a significantly shorter EFS as compared with those without (median: 6.7 vs 18.7 months, P ¼ 0.009). Moreover, the probability of relapse was significantly higher in patients carrying TET2 mutations (median time to relapse: 10.3 vs 41.3 months, P ¼ 0.005; Supplementary Figure 3a) . Further, NPM1 þ /FLT3-ITDÀ patients with additional TET2 mutations (n ¼ 15) exhibited a significantly shorter EFS (median: 10.7 vs 41.3 months, P ¼ 0.052) and a significantly higher probability of relapse (median time to relapse: 10.7 months vs not reached (n.r.), P ¼ 0.009) compared with NPM1 þ /FLT3-ITDÀ/TET2À (n ¼ 58) patients (Figure 2b ). Comparing the NPM1 þ /FLT3-ITDÀ/TET2À/IDH1/2À patients (n ¼ 38) with NPM1 þ /FLT3-ITDÀ patients, and in addition either a TET2 mutation or a IDH1/2 mutation, or both of the latter, we observed a significantly shorter EFS in the latter group (median: n.r. vs 13.3 months, P ¼ 0.027), whereas there was no difference in OS (data not shown).
When the cohort was divided into patients p65 years (n ¼ 84) and patients 465 years (n ¼ 81), we observed a significantly shorter EFS in TET2-mutated cases compared with TET2 wild-type cases in the group p65 years (median: 8.9 months vs n.r., P ¼ 0.027; Supplementary Figure 3b, left) , whereas in the cohort 465 years no such difference was found (median: 4.7 vs 9.0 months, P ¼ 0.81; Supplementary Figure 3b, right) . OS did not differ between TET2-mutated and TET2 wild-type patients within both respective groups (median: n.r. vs 62.2 months, P ¼ 0.214 for patients p65 years; 17.3 vs 9.8 months, P ¼ 0.541 for patients 465 years; Supplementary Figure 3c) . Results of univariable and multivariable analyses are shown in Supplementary Table 4. ELN criteria and the classification system of AML According to the recently defined ELN criteria, 21 we divided the cohort of 165 de novo CN-AML patients with available data on clinical follow-up into the favorable-risk category (n ¼ 81) and the intermediate-I-risk category (n ¼ 84). In line with data reported by Metzeler et al., 22 our data demonstrated that TET2-mutated patients within the favorable-risk group exhibited a significantly shorter EFS (median: 10.3 vs 41.3 months, P ¼ 0.048) and a significantly higher probability of relapse (median time to relapse: 10.7 months vs n.r., P ¼ 0.006) compared with patients without TET2 mutations (Figure 3a) . In patients of the intermediate-I-risk group, no significant difference in either EFS (median: 4.6 vs 12.1 months, P ¼ 0.102) or probability of relapse (median time to relapse: 9.6 vs 25.3 months, P ¼ 0.198) was observed (Figure 3b ).
DISCUSSION
Mutations in TET2 have recently been identified in diverse myeloid malignancies and are one of the most frequently acquired molecular aberrations associated with MDS. 13, 14 However, prognostic impact of TET2 mutations is still under controversial discussion. 12, 13, 19 We here investigated a cohort of 318 AML patients for Abbreviations: n.s., not significant; WBC, white blood cell. Ranges and percentages are given in brackets. Cytogenetic risk stratification was done according to revised MRC criteria.
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TET2 mutations in AML: incidence and prognosis S Weissmann et al mutations in TET2 with a deep-sequencing approach to obtain novel insights into prognostic relevance of TET2 mutations as well as their associations with other molecular markers. Generally, we demonstrated an overall TET2 mutation rate of 27.4% in our cohort. Overall, 42 missense variations were observed. These occurred predominantly within the two evolutionary conserved domains (35/42, 83 .3%). Missense variants located outside the conserved regions (n ¼ 7) were not included in analyses. However, nonsense and frameshift mutations are located mainly outside of the conserved domains (59/81, 72.8%). These findings suggest that missense mutations within the conserved regions result in a loss-of-function protein, whereas nonsense and frameshift mutations most probably led to a truncated protein.
Our data is therefore in line with previously published data for myeloproliferative neoplasms and MDS. 11, 13, 19, 22, 39 As TET2 mutations were first described to be involved in myeloid malignancies, 11, 12 data of polymorphisms in TET2 are constantly growing. 22, 35, 40 For example, Metzeler et al. 22 recently published that all of the seven investigated missense mutations located outside the conserved domains were germline variants. However, these data are generally controversial as Abdel-Wahab et al.
35 demonstrated 9 out of 15 missense mutations outside the conserved regions to be of somatic origin. In his data reported at the 2009 ASH conference, Nibourel et al. 41 also described seven missense mutations located outside the conserved domains that were absent in the paired remission sample. As this topic is of large interest, particularly regarding routine diagnostic assessment, we examined putative missense mutations of our AML cohort with localization inside or outside the two conserved regions for their presence or absence in germline DNA. Analyses of remission controls revealed that at least one of the investigated missense variations (Glu432Gly) located outside the two conserved regions was found to be of germline origin. Also the Pro1962Leu variation could be identified as a germline mutation. According to Langemeijer et al., 13 the Pro1962Leu mutation is located within the second conserved domain. However, in previous publications, 11, 42 the definition of the conserved regions has been slightly different because the first conserved domain covers AA 1134 --1444 and the second covers AA 1842 --1921. According to this definition, the Pro1962Leu mutation would be located outside the highly conserved regions, which would be consistent with the published data. 22 Moreover, all known polymorphisms of TET2 published in the dbSNP database are located outside the conserved domains, which is another argument in line with the data reported by Metzeler et al. 22 As such, most probably five additional putative missense mutations with localization outside the conserved regions where no remission material was available were of germline origin (Table 1) . However, only recently Bejar et al. 38 described a missense mutation with localization inside the second conserved domain to be of germline origin, indicating that missense mutations inside these conserved regions are not necessarily acquired. Yet, it seems likely that the majority of missense mutations inside the conserved regions display somatic mutations, whereas germline mutations in these domains are rare but not unlikely. To gain further insight into this topic, we used the PolyPhen-2 tool 33 to predict functional and/or structural effects of TET2 missense mutations. The results revealed that the majority (96.6%) of missense mutations located within the conserved domains could have a damaging effect on the TET2 protein structure and/or function. However, missense variations outside the conserved regions, which were supposed to be of germline origin, were found to be not necessarily benign. Of note, germline alterations can also act as negative factors promoting development of AML. For instance, it has also been shown that the synonymous IDH1 SNP rs11554137 is associated with an inferior outcome in CN-AML. 43 Furthermore, familial platelet disorder was observed to be associated with monoallelic RUNX1 germline mutations. In these patients, a second genetic event in the RUNX1 gene was shown to be frequently associated with progression to AML. 44 Possibly, this could be also the case for TET2 mutations. As such, additional research studies will be essential to clarify this important topic.
Moreover, we could demonstrate that TET2 mutations were associated with older age, higher white blood cell counts and lower platelet counts. In CN-AML patients, TET2 mutations were more frequent than in patients with aberrant karyotypes. These results are in line with recently published data. 37, 38 We found mutations in TET2 very infrequently together with IDH1 and IDH2 mutations. It has been published that cancer-associated IDH1 mutations cause the IDH1 enzyme to catalyse the onco-metabolite 2-hydroxyglutarate. 45 2-hydroxyglutarate had been identified to lead to global DNA hypermethylation and a specific hypermethylation signature, thereby impairing a catalytic function of TET2.
46
When TET2 is inactivated as a consequence of IDH mutations, it is feasible that TET2 requires not to be concomitantly inactivated by molecular mutations. Besides IDH pathway alterations, no association between TET2 mutations and other molecular markers could be demonstrated.
Inactivation of TET2 by molecular aberrations or modifications is a suggested pathogenic mechanism for the development of hematological malignancies. Therefore, when patients harbored two distinct TET2 mutations, which we could demonstrate in 50.6% (44/90) of the TET2 positive patients, it is assumed that these variations are located on different alleles. FISH analyses and methylation-specific PCR revealed that, in patients carrying only one heterozygous TET2 mutation, neither deletion nor promoter methylation of the wild-type allele were confirmed as common mechanisms to inactivate the wild-type allele. Our results concerning TET2 promotor methylation are consistent with data reported by Abdel-Wahab et al., 35 where no methylated TET2 promotor was detected in 37 myeloproliferative neoplasm patients. However, methylation-specific PCR is a technique with limited sensitivity. In particular, we could not completely exclude methylation of single CpG islands.
Finally, survival data analyses of de novo CN-AML patients revealed that TET2 mutations lead to a shorter EFS, but have only minor impact on OS. Of note, patients that have received allogeneic stem cell transplantation for consolidation therapy were not excluded or censored from analyses. But we investigated 
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Months Months Figure 3 . Kaplan --Meier survival analysis of CN-AML patients categorized according to the ELN criteria. 21 (a) EFS and probability of relapse in patients within the favorable-risk group. (b) EFS and probability of relapse in patients within the intermediate-I-risk group.
this issue and could show that allogeneic stem cell transplantation in this cohort did not influence the statistics shown in the manuscript (data not shown). Accordingly, the probability of relapse was higher in TET2-mutated patients. In particular, in patients p65 years, TET2 mutations were found to be correlated with an inferior EFS. The finding that TET2 mutations also have a negative impact on EFS in NPM1 þ /FLT3À patients, who are known to have a good prognosis, indicates that TET2 is an important biomarker, in particular within the newly defined ELN favorable-prognostic-risk group category, supporting the data published by others. 21 Taken together, TET2 mutations are of fundamental interest to improve the categorization of de novo CN-AML based on a molecular level, as has been suggested by the ELN.
In conclusion, TET2 is one of the most frequently mutated genes in AML. Because of the increasing complexity of observed molecular aberrations in this disease, future studies will be essential to clarify the clinical relevance of TET2 mutations in de novo CN-AML in the context of the molecular mutations network, regarding the respective prognostic and therapeutic role. Yet, given the inferior prognostic outcome in CN-AML patients of the ELN favorable-risk group carrying TET2 mutations, screening for TET2 mutations should be considered in order to provide an additional marker for guiding treatment decisions.
